SCHEMBL5456864

SCHEMBL5456864

COc1ccc(-c2cnc3nc(N)nc(N4CCN(c5ccccc5)CC4)c3n2)cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 7/20 0.78
GAK O14976 2/20 0.54
MAP4K1 Q92918 1/20 0.50
NEK2 P51955 1/20 0.49
KIT P10721 1/20 0.48
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
MAP3K11 Q16584 1/20 0.45
HTR7 P34969 1/20 0.45
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464535 0.91 NOS1 (0.77) NOS1GAKMAP4K1NEK2PDE4A
SCHEMBL5510661 0.89 NOS1 (0.83) NOS1GAKMAP4K1NEK2MAPT
SCHEMBL5513542 0.89 NOS1 (0.98) NOS1GAKMAP4K1NEK2KDM4E
SCHEMBL4460917 0.88 NOS1 (0.81) NOS1GAKNEK2KDM4EALDH1A1
Water SCHEMBL6499440 0.88 NOS1 (0.81) NOS1GAKMAP4K1NEK2MAPT
SCHEMBL5463796 0.88 NOS1 (0.72) NOS1GAKNEK2ALDH1A1HPGD
SCHEMBL5509568 0.88 NOS1 (1.00) NOS1GAKMAP4K1NEK2KDM4E
Water SCHEMBL6481921 0.87 NOS1 (0.80) NOS1GAKNEK2KDM4EALDH1A1
SCHEMBL5461373 0.86 NOS1 (0.69) NOS1GAKNEK2KDM4EALDH1A1
SCHEMBL5467635 0.86 NOS1 (0.69) NOS1GAKNEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673092-B1 HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY 4 AZA IP NV (BE) 2007-08-15 EP disclosed
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions 4 AZA BIOSCIENCE NV (BE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions TPMT, TYMS, TNF NOS1 107/4885GAK 2048/4885MAP4K1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.